Verona Pharma
Biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases.
Launch date
Employees
Market cap
AUD3.8b
Enterprise valuation
AUD3.8b (Public information from Sep 2024)
Share price
£0.5489 VRP.L
Company register number 05375156
Cardiff Wales (HQ)
Financials
Estimates*
GBP | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | - | 30.0m | <1m | - | 5.4m | 64.9m | 297m |
% growth | - | - | (99 %) | - | - | 1105 % | 358 % |
EBITDA | (52.0m) | (60.3m) | (64.3m) | - | - | - | - |
% EBITDA margin | - | (201 %) | (16929 %) | - | - | - | - |
Profit | (46.0m) | (42.0m) | (57.0m) | (43.0m) | (142m) | (94.8m) | 88.7m |
% profit margin | - | (140 %) | (15000 %) | - | (2647 %) | (146 %) | 30 % |
EV / revenue | - | 7.2x | 4155.3x | - | 315.6x | 26.2x | 5.7x |
EV / EBITDA | -3.1x | -3.6x | -24.5x | - | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
$11.5m | Post IPO Equity | ||
£44.7m | Post IPO Equity | ||
* | N/A | $77.1m Valuation: $163m -17.9x EV/LTM EBITDA | IPO |
$200m | Post IPO Equity | ||
$30.0m | Post IPO Debt | ||
* | N/A | $130m | Post IPO Equity |
* | $150m | Post IPO Debt | |
* | $400m | Post IPO Debt | |
* | $250m | Post IPO Equity | |
Total Funding | - |
Related Content
Recent News about Verona Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.